Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

Highlights • Afatinib, erlotinib, and gefitinib are available for EGFR mutation-positive NSCLC. • Severe rash and diarrhea were more frequent with afatinib treatment. • Severe hepatotoxicity was more frequent with gefitinib treatment.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-04, Vol.88 (1), p.74-79
Hauptverfasser:	Takeda, Masayuki, Okamoto, Isamu, Nakagawa, Kazuhiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Afatinib Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Chemical and Drug Induced Liver Injury - etiology ErbB Receptors - genetics Erlotinib Hydrochloride - adverse effects Erlotinib Hydrochloride - therapeutic use Gefitinib Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Mutation Pulmonary/Respiratory Quinazolines - adverse effects Quinazolines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Afatinib, erlotinib, and gefitinib are available for EGFR mutation-positive NSCLC. • Severe rash and diarrhea were more frequent with afatinib treatment. • Severe hepatotoxicity was more frequent with gefitinib treatment.
ISSN:	0169-5002 1872-8332 1872-8332
DOI:	10.1016/j.lungcan.2015.01.026